The improved net loss is a one-time licensing event; the underlying operating loss widened. With cash only through Q4 2026 and no approved products, the company will likely need to raise capital within 6-12 months, creating dilution risk for a $29M market cap stock. Monitor for financing announcements and the B-SUPREME topline data expected in late Q3 2027.
Price Chart
Executive Summary
Aligos Therapeutics reported Q2 2026 financial results with a net loss of $1.5M ($-0.14/share), a significant improvement from the $15.9M loss ($-1.53/share) in Q2 2025, driven by $27.8M in licensing revenue from the Amoytop deal. Pipeline progress includes completion of enrollment for the Phase 2 B-SUPREME study and Breakthrough Therapy Designation in China for pevifoscorvir sodium, but cash runway only extends through Q4 2026, creating a financing overhang for a $29M market cap company with no approved products. The improved net loss is largely non-recurring licensing revenue, not operational progress, making this a mixed filing with a neutral-to-slightly-bearish lean given the cash burn rate and lack of near-term revenue visibility.
Key Financial Metrics
Key Facts
- Net loss improved to $1.5M ($-0.14/share) in Q2 2026 from $15.9M ($-1.53/share) in Q2 2025, primarily due to $27.8M in licensing revenue from the Amoytop deal.
- Cash, cash equivalents and investments totaled $30.4M as of June 30, 2026, excluding the $25M Amoytop upfront received in July 2026; cash expected to fund operations only through Q4 2026.
- Phase 2 B-SUPREME study for pevifoscorvir sodium completed enrollment (131 HBeAg+ and 114 HBeAg- participants); topline data expected in late Q3 2027.
- Pevifoscorvir sodium granted Breakthrough Therapy Designation in China from the CDE/NMPA.
- Partner Amoytop received IND approval in China for ALG-170675 (ASO), triggering a $3M milestone payment expected in Q3 2026.
- R&D expenses increased to $24.1M from $14.0M year-over-year, driven by the Phase 2 trial costs.
Financial Impact
Net loss improved by $14.4M YoY to $1.5M, but this was entirely due to $27.8M in non-recurring licensing revenue; operating loss (ex-licensing) was $29.7M vs $19.5M a year ago. Cash burn remains high at ~$24M/quarter in operating expenses.
Risk Factors
- Cash runway only through Q4 2026; likely need for dilutive financing within 6-12 months.
- No approved products or near-term revenue; topline data from B-SUPREME not expected until late Q3 2027.
- R&D expenses continue to rise, widening operating losses.
- Pre-revenue clinical-stage biotech with high cash burn relative to market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005294 |
| Document: f8k_080526.htm | 0001171843-26-005294 |
| Document: 0001171843-26-005294-index-headers.html | 0001171843-26-005294 |
| Document: 0001171843-26-005294-index.html | 0001171843-26-005294 |
| Document: 0001171843-26-005294.txt | 0001171843-26-005294 |
| 8-K Data (Synthetic) | 0001171843-26-005294 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $5.51 $6.77 | ▲ +22.87% | ▲ +21.65% | $4.68 (−15.15%) |
Jun 26, 2026 17w ago | 8-K | $5.43 $5.85 | ▲ +7.73% | ▲ +6.35% | $4.68 (−13.90%) |
May 27, 2026 21w ago | Press Release | $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | $4.68 (−16.52%) |
Apr 16, 2026 27w ago | Press Release | $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | $4.68 (−38.97%) |
Apr 14, 2026 27w ago | Press Release | $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | $4.68 (−36.99%) |
Mar 5, 2026 33w ago | 8-K | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.68 (−29.80%) |
Mar 5, 2026 33w ago | Press Release | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.68 (−29.80%) |
Feb 28, 2026 34w ago | Institutional Cluster | $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | $4.68 (−32.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers